OMIM : 603700
GENECARD : ALOX5AP
CGAP : 100194
Chromsome human
Cytogenetic and radiation hybrid mapping of human arachidonate 5-lipoxygenase-activating protein (ALOX5AP) to chromosome 13q12. Yandava CN, Kennedy BP, Pillari A, Duncan AM, Drazen JM.
Clinical
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ferry DR, Deakin M, Baddeley J, Daryanani S, Bramhall S, Anderson DA, Wakelam MJ, Doran J, Pemberton G, Young AM, Buckels J, Kerr DJ
Altered oncogene, tumor suppressor and cell-cycle gene expression in PANC-1 cells cultured with the pleiotrophic 5-lipoxygenase inhibitor, MK886, assessed with a gene chip. Anderson KM, Alrefai WA, Bonomi P, Dudeja P, Ou D, Anderson C, Harris JE.
Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Ding XZ, Iversen P, Cluck MW, Knezetic JA, Adrian TE.
Five-lipoxygenase inhibitors reduce Panc-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid. Anderson KM, Seed T, Meng J, Ou D, Alrefai WA, Harris JE.
DNA Structure
Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP). Kennedy BP, Diehl RE, Boie Y, Adam M, Dixon RA.
Regulation
Recent studies have shown overexpression of cyclooxygenase 2 (COX 2) and 5-lipoxygenase (5-lipox) in exocrine pancreatic carcinomas. Weddle DL, Tithoff P, Williams M, Schuller HM.